Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresh Australian Industry Pact Will Insure Against Shortages

New Five-Year Strategic Agreement Signed Between Government And GBMA

Executive Summary

A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.

You may also be interested in...



Australian Industry Signs Deal To Fund Access To Innovative New Drugs

Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.

GBMA Set For New Australian Pact

Australian off-patent industry association the GBMA says it has begun negotiations on a new strategic agreement with the government that will offer “long-term certainty” for the sector. Meanwhile, the industry body has praised the latest “pandemic budget” measures to address the impact of COVID-19.

Australia Allows Industry Collaboration To Continue

Australia’s competition authority has extended the arrangements allowing local off-patent industry body the GBMA to closely collaborate with brand organization Medicines Australia to co-ordinate supply against the backdrop of the ongoing COVID-19 pandemic.

Topics

UsernamePublicRestriction

Register

GB151221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel